Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema Registry Taskforce

Accepted/In Press date: 8 August 2022

e-pub ahead of print date: 10 September 2022

Published date: January 2023

Additional Information: Funding Information: P.I. Spuls has done consultancies in the past for Sanofi 111017 and AbbVie 041217 (unpaid), received a departmental independent research grants from pharmaceutical industries since December 2019 for the TREAT NL registry, is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of e.g. psoriasis and atopic dermatitis, for which financial compensation is paid to the department/hospital and, is Chief Investigator (CI) of the systemic and phototherapy atopic eczema registry (TREAT NL) for adults and children and one of the main investigators of the SECURE‐AD registry. C. Flohr is Chief Investigator of the UK National Institute for Health Research–funded TREAT (ISRCTN15837754) and SOFTER ( ClinicalTrials.gov : NCT03270566) trials and the UK‐Irish Atopic Eczema Systemic Therapy Register (A‐STAR; ISRCTN11210918) and is a principal investigator in the European Union Horizon 2020–funded BIOMAP Consortium ( http://www.biomap‐imi.eu/ ). He is also Chief Investigator of the EU Joint Program Initiative TRANS‐FOODS consortium. His department has also received investigator‐led funding from Sanofi‐Genzyme for skin microbiome work. L.A.A. Gerbens is one of the main investigators of the TREAT NL registry. She has no further conflicts of interest. A. Chiricozzi is advisory board member, consultant, speaker, investigator in clinical trials for AbbVie, Almirall, Biogen, Fresenius Kabi, Leo Pharma, Lilly, Janssen, Novartis, Sanofi Genzyme and UCB Pharma. M.A. Middelkamp‐Hup is consultant for Sanofi and Pfizer and one of the main investigators of the TREAT NL registry. E.K. Johansson received speaker honoraria and/or been a consultant for AbbVie, ACO, Galenica, LEO Pharma, Novartis, and Sanofi‐Genzyme. E. Haufe is coordinator of TREATgermany; no further conflicts of interest. J. Schmitt is PI of TREATgermany; institutional funding of IITs from Sanofi, Novartis, Pfizer, ALK; consultancies for Sanofi, Lilly, Novartis, ALK. I. García‐Doval received financial compensation for talks unrelated to atopic dermatitis from UCB and Novartis, and a travel grant from Janssen. N. J. Reynolds has received, through Newcastle University, research grant funding, funding for lectures and/or travel support from Celgene, Genentech and Sanofi‐Genzyme. M. R. Ardern‐Jones has acted as a collaborative researcher/consultant/speaker for AbbVie, Pfizer, Sanofi Genzyme, Ducentis, Hosei Septares, Leo Pharma, Novartis. I. Vittrup has received salary from research funding from Sanofi and Regeneron Pharmaceuticals, Inc. S. Barbarot is investigator or speaker for Almirall, Sanofi‐Genzyme, Abbvie, Novartis, Janssen, Leo‐Pharma, Pfizer, Eli Lilly, UCB Pharma. D. Staumont‐Sallé is investigator or speaker or member of advisory board for Abbvie, AstraZeneca, Eli Lilly, Galderma, Janssen, Leo‐Pharma, Novartis, Pfizer, Sanofi‐Genzyme, UCB Pharma. J. Seneschal is investigator or speaker or member of advisory board for Abbvie, Eli Lilly, Galderma, Janssen, Leo‐Pharma, Novartis, Pfizer, Sanofi‐Genzyme. J. Thyssen is advisor, speaker or investigator for Abbvie, Arena, Pfizer, LEO Pharma, Regeneron, Sanofi‐Genzyme, Almirall, and Eli Lilly. He has received research grants from Regeneron and Sanofi‐Genzyme. C. Vestergaard is Speaker/honorarium for Sanofi, Leo Pharma, Abbvie, Pfizer, Pierre Fabre, AstraZeneca. No other disclosures were reported. Publisher Copyright: © 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

Local EPrints ID: 471355

URI: http://eprints.soton.ac.uk/id/eprint/471355

DOI: doi:10.1111/jdv.18566

ISSN: 0926-9959

PURE UUID: 69bd0f7c-ec0a-4d3b-947b-1da62fc68976

ORCID for Michael R. Ardern-Jones: orcid.org/0000-0003-1466-2016

Date deposited: 03 Nov 2022 18:00

Last modified: 17 Mar 2024 07:33